Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). [electronic resource] by
- Tinker, A V
- Ellard, S
- Welch, S
- Moens, F
- Allo, G
- Tsao, M S
- Squire, J
- Tu, D
- Eisenhauer, E A
- MacKay, H
Producer: 20130913
In:
Gynecologic oncology vol. 130
Availability: No items available.
|
|
8.
|
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. [electronic resource] by
- Nehra, J
- Bradbury, P A
- Ellis, P M
- Laskin, J
- Kollmannsberger, C
- Hao, D
- Juergens, R A
- Goss, G
- Wheatley-Price, P
- Hotte, S J
- Gelmon, K
- Tinker, A V
- Brown-Walker, P
- Gauthier, I
- Tu, D
- Song, X
- Khan, A
- Seymour, Lesley
- Smoragiewicz, M
Producer: 20210902
In:
Investigational new drugs vol. 38
Availability: No items available.
|
|
9.
|
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. [electronic resource] by
- He, Y
- Wu, A C
- Harrington, B S
- Davies, C M
- Wallace, S J
- Adams, M N
- Palmer, J S
- Roche, D K
- Hollier, B G
- Westbrook, T F
- Hamidi, H
- Konecny, G E
- Winterhoff, B
- Chetty, N P
- Crandon, A J
- Oliveira, N B
- Shannon, C M
- Tinker, A V
- Gilks, C B
- Coward, J I
- Lumley, J W
- Perrin, L C
- Armes, J E
- Hooper, J D
Producer: 20160620
In:
Oncogene vol. 35
Availability: No items available.
|